Peripheral Vascular Disease Clinical Trial
— THEMOfficial title:
Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections Following Arterial Revascularization With Groin Incision
NCT number | NCT02767011 |
Other study ID # | 15-169 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | July 2017 |
Verified date | April 2019 |
Source | CAMC Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Abstract:
It is intuitive that post discharge surgical complications are associated with increased
patient dissatisfaction, and directly associated with an increase in medical expenditures. It
is also easy to make the connection that many post hospital discharge surgical complications
including surgical site infections could be influenced or exacerbated by patient
co-morbidities. The authors of a recent study reported that female gender, obesity, diabetes,
smoking, hypertension, coronary artery disease, critical limb ischemia, chronic obstructive
pulmonary disease, dyspnea, and neurologic disease were all of among significant predictors
of surgical site infections after vascular reconstruction was performed. The main concern for
optimal patient care especially in geographically isolated areas of West Virginia is to have
early, expeditious, and prompt diagnosis of early surgical site infection with subsequent
indicated interventions. This theme will lead to patient satisfaction, minimizing third party
interventions and decrease the total cost associated with these complications. Nevertheless,
it seems reasonable to believe that monitoring using telehealth technology and managing the
general health care patients receive after a hospital vascular intervention will improve
overall health and reduce post-operative complications.
Aims/Objectives:
1. The primary objective of the current project is to compare early and late outcomes for
patients who receive post discharge health care monitoring (which includes using Telehealth
electronic monitoring; THEM) to patients who receive standard of care (SOC) and routine
discharge instructions and no monitoring.
Methods:
1. Randomize patients who are scheduled to have revascularization interventions with groin
incisions to receive either telehealth electronic health care monitoring or normal
standard of follow-up care.
2. Follow patients for 4 weeks, record any 30-day hospital readmissions or complications.
In addition, have participants complete the follow-up survey questionnaires.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: 1. Patients with any planned vascular procedures with cut-down access to the groin and treated by one of the Charleston Area Medical Center -Vascular Surgeons in the Vascular Center (VCOE) will be consented and enrolled. Exclusion Criteria: 1. do not plan to do follow-up visit at the VCOE; 2. history of dementia; 3. do not have home internet service with WIFI or live outside of the provided cell coverage area (cell coverage will be provided for patients without internet WIFI). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CAMC Health System | WVCTSI |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 30-Day Readmission (Any) | Yes/No was patient readmitted? Patients were monitored for 30 days to see if they were re-admitted to the hospital for any reason. Percentage of patients with 30-day readmission. | 30-day | |
Primary | 30-day Wound Readmission | Yes/No was patient readmitted for wound infection? Patients were monitored for 30 days to see if they were re-admitted to the hospital for wound infection. Percentage of patients with 30-day readmission for wound infection. | 30-day | |
Primary | Access Site/Wound Infections. | Yes/No did patient any access site or would infections? Access site wounds for the patients were monitored for 30 days for any wound infections. | 30-day | |
Secondary | The Difference Between Baseline and 30-day Quality of Life (Short-Form 8) Physical Summary Score | The Difference between baseline and 30-day quality of life (Short-Form 8) Physical summary T-scores. The short-form (SF-8) Health Survey is an 8-item survey designed to measure quality of life. The SF-8 has 8 questions that first measures eight ordinal items (i.e., 1-5 Likert scale): general health, physical health functioning, role physical, bodily pain, vitality, social functioning, mental health and emotional roles. Summing the responses of the 8 items can be used to report an overall measure of physical and mental functioning. The raw Likert scale scores are converted to normalized standard T scores with a mean of 50 and standard deviation of 10. Measuring physical and mental health both before and after an intervention, as continuous summary scores can indicate better self-reported quality of life with higher scores. A difference score of 0 would indicate no change, while a larger positive difference score would indicate an increase in self-reported quality of life. | 30-day | |
Secondary | Patient Satisfaction as Measured by the General Satisfaction Sub-scale of the Short-Form Patient Satisfaction Questionnaire (PSQ18) | Patients' satisfaction was compared using the General Satisfaction sub-scale of the Short-Form Patient Satisfaction Questionnaire (PSQ18). The PSQ-18 contains 18 items (questions) that can measure seven dimensions of satisfaction: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Responses to the PSQ-18 require a selection on a Likert scale from 1 Strongly Agree to 5 Strongly Disagree with some of the questions worded in such a manner that agreement reflects greater satisfaction (1, 2, 3, 5, 6, 8, 11, 15 & 18). These responses were "re-coded" in order for a larger number to reflect greater satisfaction. Next, two individual items (3 and 17) are summed and averaged to produce the general satisfaction sub-scale. A larger number reflects greater satisfaction, with a range of 1 to 5. | 30-day | |
Secondary | Number of Participants With Home Nursing Visits | Yes/No did the patient have (any) home nursing visits during the 30-day follow-up period. | 30-day | |
Secondary | Stroke | Yes/No did patient have a stroke. Patients were monitored for 30 days for stroke. | 30-day | |
Secondary | Myocardial Infarction | Yes/No did patient have myocardial infarction. Patients were monitored for 30 days for myocardial infarction. | 30-day | |
Secondary | Death | Yes/No Did patient die? Patients for monitored for 30 days for death. | 30-day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05335525 -
Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
|
||
Active, not recruiting |
NCT01903044 -
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
|
Phase 1/Phase 2 | |
Completed |
NCT02271529 -
Zilver PTX Delivery System
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Recruiting |
NCT02054871 -
RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Completed |
NCT00574782 -
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
|
N/A | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Completed |
NCT01355406 -
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
|
N/A | |
Recruiting |
NCT05804097 -
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
|
Phase 4 | |
Recruiting |
NCT03638115 -
The VaSecure BTK Study
|
N/A | |
Active, not recruiting |
NCT03241459 -
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
|
N/A | |
Active, not recruiting |
NCT01661231 -
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
|
N/A | |
Completed |
NCT01722877 -
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
|
N/A | |
Completed |
NCT01444378 -
Absolute Pro® MOMENTUM™
|
N/A | |
Completed |
NCT00753337 -
The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
|
N/A | |
Completed |
NCT00538226 -
Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
|
Phase 1 | |
Completed |
NCT00593385 -
Atrium iCAST Iliac Stent Pivotal Study
|
N/A | |
Recruiting |
NCT00385385 -
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
|
Phase 2 | |
Completed |
NCT00392509 -
ALD-301 for Critical Limb Ischemia, Randomized Trial
|
Phase 1/Phase 2 |